Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (90)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (2)
Clinical guidelines (25)
Diagnostics guidance (2)
Highly specialised technologies guidance (2)
Interventional procedures guidance (30)
Medical technologies guidance (14)
NICE guidelines (29)
Public health guidelines (1)
Social care guidelines (3)
Technology appraisal guidance (90)
Apply filters
Showing 1 to 90 of 90
Sort by
Date
Title
Apply sorting
Last updated date between 1/1/2021 and 1/1/2022
Remove Last updated date between 1/1/2021 and 1/1/2022 filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
TA756
16 December 2021
16 December 2021
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
TA752
15 December 2021
15 December 2021
Cenobamate for treating focal onset seizures in epilepsy
TA753
15 December 2021
15 December 2021
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
TA754
15 December 2021
15 December 2021
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)
TA750
8 December 2021
8 December 2021
Dupilumab for treating severe asthma with type 2 inflammation
TA751
8 December 2021
8 December 2021
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
TA748
1 December 2021
1 December 2021
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
TA749
1 December 2021
1 December 2021
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
TA746
17 November 2021
17 November 2021
Nintedanib for treating progressive fibrosing interstitial lung diseases
TA747
17 November 2021
17 November 2021
Upadacitinib for treating moderate rheumatoid arthritis
TA744
10 November 2021
10 November 2021
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)
TA745
10 November 2021
10 November 2021
Selpercatinib for treating advanced thyroid cancer with RET alterations
TA742
3 November 2021
3 November 2021
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
TA740
28 October 2021
28 October 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
TA741
28 October 2021
28 October 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
TA739
27 October 2021
27 October 2021
Tofacitinib for treating juvenile idiopathic arthritis
TA735
20 October 2021
20 October 2021
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
TA736
20 October 2021
20 October 2021
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
TA737
20 October 2021
20 October 2021
Berotralstat for preventing recurrent attacks of hereditary angioedema
TA738
20 October 2021
20 October 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people
TA734
7 October 2021
7 October 2021
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)
TA732
6 October 2021
6 October 2021
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
TA733
6 October 2021
6 October 2021
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)
TA730
29 September 2021
29 September 2021
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)
TA731
29 September 2021
29 September 2021
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
TA726
22 September 2021
22 September 2021
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
TA727
22 September 2021
22 September 2021
Midostaurin for treating advanced systemic mastocytosis
TA728
22 September 2021
22 September 2021
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
TA729
22 September 2021
22 September 2021
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA725
15 September 2021
15 September 2021
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
TA724
8 September 2021
8 September 2021
Bimekizumab for treating moderate to severe plaque psoriasis
TA723
1 September 2021
1 September 2021
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA722
25 August 2021
25 August 2021
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome
TA139
26 March 2008
20 August 2021
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
TA720
18 August 2021
18 August 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
TA721
18 August 2021
18 August 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA716
28 July 2021
28 July 2021
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)
TA717
21 July 2021
21 July 2021
Ixekizumab for treating axial spondyloarthritis
TA718
21 July 2021
21 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis
TA719
21 July 2021
21 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
TA714
14 July 2021
14 July 2021
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA715
14 July 2021
14 July 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA712
7 July 2021
7 July 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA713
7 July 2021
7 July 2021
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
TA275
27 February 2013
2 July 2021
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
TA249
15 March 2012
2 July 2021
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
TA256
23 May 2012
2 July 2021
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
TA355
23 September 2015
2 July 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA708
23 June 2021
23 June 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA709
23 June 2021
23 June 2021
Ravulizumab for treating atypical haemolytic uraemic syndrome
TA710
23 June 2021
23 June 2021
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA707
15 June 2021
15 June 2021
Ozanimod for treating relapsing–remitting multiple sclerosis
TA706
9 June 2021
9 June 2021
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA705
2 June 2021
2 June 2021
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)
TA702
26 May 2021
26 May 2021
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)
TA703
26 May 2021
26 May 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA704
26 May 2021
26 May 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
TA698
19 May 2021
19 May 2021
Ofatumumab for treating relapsing multiple sclerosis
TA699
19 May 2021
19 May 2021
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA700
19 May 2021
19 May 2021
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)
TA701
19 May 2021
19 May 2021
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
TA696
12 May 2021
12 May 2021
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
TA697
12 May 2021
12 May 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
TA692
28 April 2021
28 April 2021
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
TA694
28 April 2021
28 April 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
TA695
28 April 2021
28 April 2021
Avelumab for treating metastatic Merkel cell carcinoma
TA517
11 April 2018
21 April 2021
Acalabrutinib for treating chronic lymphocytic leukaemia
TA689
21 April 2021
21 April 2021
Avelumab for untreated metastatic Merkel cell carcinoma
TA691
21 April 2021
21 April 2021
Anakinra for treating Still's disease
TA685
31 March 2021
31 March 2021
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
TA686
31 March 2021
31 March 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA687
31 March 2021
31 March 2021
Selective internal radiation therapies for treating hepatocellular carcinoma
TA688
31 March 2021
31 March 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
TA684
17 March 2021
17 March 2021
Erenumab for preventing migraine
TA682
10 March 2021
10 March 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
TA683
10 March 2021
10 March 2021
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
TA680
3 March 2021
3 March 2021
Baricitinib for treating moderate to severe atopic dermatitis
TA681
3 March 2021
3 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis
TA676
24 February 2021
24 February 2021
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
TA677
24 February 2021
24 February 2021
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
TA678
24 February 2021
24 February 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
TA679
24 February 2021
24 February 2021
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
TA673
17 February 2021
17 February 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
TA674
17 February 2021
17 February 2021
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)
TA675
17 February 2021
17 February 2021
Trabectedin for the treatment of advanced soft tissue sarcoma
TA185
24 February 2010
8 February 2021
Mepolizumab for treating severe eosinophilic asthma
TA671
3 February 2021
3 February 2021
Brolucizumab for treating wet age-related macular degeneration
TA672
3 February 2021
3 February 2021
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
TA670
27 January 2021
27 January 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
TA668
6 January 2021
6 January 2021
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top